Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Insaco
Baltimore, Maryland, United Statesinsaco.com ↗
- Ownership
- Private
- Employees
- ~160
- Development stage
- Commercial
01
Overview
Insilico’s lead program Rentosertib/ISM001–055 for idiopathic pulmonary fibrosis completed a Phase IIa trial with favorable safety/tolerability and dose-dependent efficacy. Multiple additional assets have reached IND or early clinical stages across oncology and immunology. The company has outlicensed several programs to major pharma partners with significant milestone payments achieved.
- Therapeutic areas
- PulmonologyOncologyEndocrinologyImmunologyOtherGastroenterologyNeurologyInfectious Diseases
- Modalities
- Small moleculeBiologicAntibodymRNA-based drugsPeptides
- Industry
- Biotech
02
Partnerships
Beyond the preview
Go deeper on Insaco.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Insaco.